Square Pharmaceuticals PLC (SQURPHARMA)
A
| Pharmaceuticals & Chemicals
INTRADAY 1MIN CHART
Loading ...
Price: -
Volume: -
Today Analysis
Square Pharmaceuticals PLC. এর শেয়ারটি 217.20 BDT-এ লেনদেন হচ্ছে, যা বর্তমান ট্রেন্ডে বাড়তির দিকে। কোম্পানিটির NAV 157.88 BDT-এ অবস্থান করছে, যা দীর্ঘমেয়াদী বিনিয়োগের জন্য একটি নির্দেশক হিসেবে কাজ করে। কোম্পানির P/E Ratio নির্দেশ করে এটি তুলনামূলকভাবে আয়ের চেয়ে কতগুণ বেশি মূল্যে লেনদেন হচ্ছে। টেকনিক্যাল এনালাইসিস অনুযায়ী, সাপোর্ট লেভেল 210.68 BDT-এর কাছাকাছি হতে পারে, যেখানে শেয়ারটি ঘুরে দাঁড়াতে পারে। অন্যদিকে 224.80 BDT-এ একটি সম্ভাব্য রেজিস্ট্যান্স আছে, যেখানে দাম বাধা পেতে পারে। বিনিয়োগের সিদ্ধান্ত নেওয়ার আগে, মার্কেটের সামগ্রিক অবস্থা ও কোম্পানির ফান্ডামেন্টালগুলো বিবেচনা করা জরুরি।
(Disclaimer: This system generated summary is for informational purposes only and does not constitute financial advice.)
Market Depth (Live Order Book)
Buy Orders (Bids)
| Cum Qty | Volume | Price |
|---|---|---|
| No buy orders | ||
Sell Orders (Asks)
| Price | Volume | Cum Qty |
|---|---|---|
| No sell orders | ||
| Date | Close | Volume | Trade | Change | Ch(%) | Open | High | Low |
|---|---|---|---|---|---|---|---|---|
| Loading historical data... | ||||||||
29 Jun, 2026
SQURPHARMA: Contract Manufacturing Agreement with M/s C2C Pharma Ltd.
The company has informed that the Board of Directors of the company in its meeting held on 28 June 2026 has approved agreements with M/s C2C Pharma Ltd., Dhaka, Bangladesh for contract manufacturing of some products on behalf of Square Pharmaceuticals PLC. to meet increased demand of existing products and to introduce new products. It is mentionable that DSE has requested the company to provide copy of the agreement; however, DSE is yet to receive the copy of the agreement.
30 Apr, 2026
SQURPHARMA: Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.73 for January-March 2026 as against Tk. 6.83 for January-March 2025; Consolidated EPS was Tk. 23.29 for July 2025-March 2026 as against Tk. 21.15 for July 2024-March 2025. Consolidated NOCFPS was Tk. 17.54 for July 2025-March 2026 as against Tk. 11.90 for July 2024-March 2025. Consolidated NAV per share was Tk. 169.79 as on March 31, 2026 and Tk. 157.88 as on June 30, 2025. (cont.)
26 Apr, 2026
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2026 at 3:00 pm to consider, among others, Un-Audited Financial Statements for the Third Quarter (Q3) period ended March 31, 2026.
23 Feb, 2026
SQURPHARMA: Buy Confirmation of Chairman
Mr. Samuel S Chowdhury, Chairman of the Company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 20.01.2026.
05 Feb, 2026
SQURPHARMA: Buy Confirmation of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has further informed that she has completed her buying of 1,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 15.01.2026.
05 Feb, 2026
SQURPHARMA: Buy Confirmation of Managing Director
Mr. Tapan Chowdhury, Managing Director of the company, has further informed that he has completed his buying of 2,000,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 5.01.2026.
01 Feb, 2026
SQURPHARMA: Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 8.20 for October-December 2025 as against Tk. 7.45 for October-December 2024; Consolidated EPS was Tk. 16.56 for July-December 2025 as against Tk. 14.32 for July-December 2024. Consolidated NOCFPS was Tk. 13.16 for July-December 2025 as against Tk. 8.28 for July-December 2024. Consolidated NAV per share was Tk. 162.41 as on December 31, 2025 and Tk. 157.88 as on June 30, 2025. (cont.)
25 Jan, 2026
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 29, 2026 at 3:00 PM to consider, among others, Un-Audited Financial Statements for the Second Quarter (Q2) period ended December 31, 2025.
21 Jan, 2026
SQURPHARMA: Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2025 to the respective shareholders.
20 Jan, 2026
SQURPHARMA: Buy Declaration of Chairman
Mr. Samuel S Chowdhury, Chairman of the Company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
15 Jan, 2026
SQURPHARMA: Buy Declaration of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 10,00,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
05 Jan, 2026
SQURPHARMA: Buy Declaration of Managing Director
Mr. Tapan Chowdhury, Managing Director of the company, has expressed his intention to buy 20,00,000 shares of the company at prevailing market price (in the Public/Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
14 Dec, 2025
SQURPHARMA: Credit Rating Result
Credit Rating Information and Services PLC (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2025; unaudited financials up to September 30, 2025 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
16 Nov, 2025
SQURPHARMA: Resumption after Record Date
Trading of the shares of the company will resume on 17.11.2025.
13 Nov, 2025
SQURPHARMA: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 8.35 for July-September 2025 as against Tk. 6.87 for July-September 2024; Consolidated NOCFPS was Tk. 7.55 for July-September 2025 as against Tk. 3.89 for July-September 2024. Consolidated NAV per share was Tk. 167.50 as on September 30, 2025 and Tk. 157.88 as on June 30, 2025.
13 Nov, 2025
SQURPHARMA: Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 16.11.2025.
11 Nov, 2025
SQURPHARMA: Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 12.11.2025 to 13.11.2025 and trading of the shares will remain suspended on record date i.e., 16.11.2025.
06 Nov, 2025
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 12, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2025.
23 Oct, 2025
SQURPHARMA: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (23.10.2025) following its corporate declaration.
23 Oct, 2025
SQURPHARMA: Dividend Declaration and Others
The Board of Directors has recommended 120% Cash Dividend for the year ended June 30, 2025. Date of AGM: 15.12.2025, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 16.11.2025. The Company has also reported Consolidated EPS of Tk. 27.04, Consolidated NAV per share of Tk. 157.88 and Consolidated NOCFPS of Tk. 19.52 for the year ended June 30, 2025 as against Tk. 23.61, Tk. 142.05 and Tk. 20.90 respectively for the year ended June 30, 2024. (cont.)
12 Oct, 2025
SQURPHARMA: Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 22, 2025 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2025.
30 Apr, 2025
SQURPHARMA: Q3 Financials
(Q3 Un-audited): Consolidated EPS was Tk. 6.83 for January-March 2025 as against Tk. 5.55 for January-March 2024; Consolidated EPS was Tk. 21.15 for July 2024-March 2025 as against Tk. 18.24 for July 2023-March 2024. Consolidated NOCFPS was Tk. 11.90 for July 2024-March 2025 as against Tk. 17.32 for July 2023-March 2024. Consolidated NAV per share was Tk. 151.94 as on March 31, 2025 and Tk. 142.05 as on June 30, 2024. (cont.)
22 Apr, 2025
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on April 29, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Third Quarter (Q3) period ended March 31, 2025.
20 Apr, 2025
SQURPHARMA: Buy Confirmation of a Director
Mr. Samuel S Chowdhury, one of the Directors of the Company, has further informed that he has completed his buying of 1,500,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 10.03.2025.
23 Mar, 2025
SQURPHARMA: Buy Confirmation of Managing Director
Mr. Tapan Chowdhury, the Managing Director of the Company, has further informed that he has completed his buying of 15,00,000 shares of the company at prevailing market price through Dhaka Stock Exchange PLC. as per declaration disseminated on 04.03.2025.
12 Mar, 2025
SQURPHARMA: Buy Declaration of a Director
Mrs. Ratna Patra, one of the Directors of the Company, has expressed her intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
10 Mar, 2025
SQURPHARMA: Buy Declaration of a Director
Mr. Samuel S Chowdhury, one of the Directors of the Company, has expressed his intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
10 Mar, 2025
SQURPHARMA: Buy Confirmation of a Director
Mr. Anjan Chowdhury, a Director of the Company, has completed his purchase of 1,500,000 shares of the Company at prevailing market through Dhaka Stock Exchange PLC. as per declaration disseminated on 18.02.2025.
04 Mar, 2025
SQURPHARMA: Buy Declaration of Managing Director
Mr. Tapan Chowdhury, Managing Director of the Company, has expressed his intention to buy 1,500,000 shares of the company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
18 Feb, 2025
SQURPHARMA: Buy Declaration of Director
Mr. Anjan Chowdhury, a Director of the Company, has expressed his intention to buy 1,500,000 shares of the Company at prevailing market price (in the Public and Block Market) through Dhaka Stock Exchange PLC. within next 30 working days.
02 Feb, 2025
SQURPHARMA: Q2 Financials
(Q2 Un-audited): Consolidated EPS was Tk. 7.45 for October-December 2024 as against Tk. 5.92 for October-December 2023; Consolidated EPS was Tk. 14.32 for July-December 2024 as against Tk. 12.69 for July-December 2023. Consolidated NOCFPS was Tk. 8.28 for July-December 2024 as against Tk. 14.37 for July-December 2023. Consolidated NAV per share was Tk. 145.52 as on December 31, 2024 and Tk. 142.05 as on June 30, 2024.
28 Jan, 2025
SQURPHARMA: Dividend Disbursement
The Company has informed that it has disbursed the Cash Dividend for the year ended June 30, 2024 to the respective shareholders.
27 Jan, 2025
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on January 30, 2025 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the Second Quarter (Q2) period ended December 31, 2024.
15 Dec, 2024
SQURPHARMA: Credit Rating Result
Credit Rating Information and Services Limited (CRISL) has assigned the rating of the Company as "AAA" in the long term and "ST-1" in the short term along with Stable outlook in consideration of its audited financials up to June 30, 2024; unaudited financials up to September 30, 2024 and other relevant quantitative as well as qualitative information up to the date of rating declaration.
21 Nov, 2024
SQURPHARMA: Resumption after Record Date
Trading of the shares of the company will resume on 24.11.2024.
20 Nov, 2024
SQURPHARMA: Suspension for Record Date
Trading of the shares of the company will remain suspended on record date i.e., 21.11.2024.
18 Nov, 2024
SQURPHARMA: Spot News
Trading of the shares of the company will be allowed only in the Spot Market and Block transaction will also be settled as per spot settlement cycle with cum benefit from 19.11.2024 to 20.11.2024 and trading of the shares will remain suspended on record date i.e., 21.11.2024.
17 Nov, 2024
SQURPHARMA: Q1 Financials
(Q1 Un-audited): Consolidated EPS was Tk. 6.87 for July-September 2024 as against Tk. 6.77 for July-September 2023; Consolidated NOCFPS was Tk. 3.89 for July-September 2024 as against Tk. 9.54 for July-September 2023. Consolidated NAV per share was Tk. 149.76 as on September 30, 2024 and Tk. 142.05 as on June 30, 2024.
12 Nov, 2024
SQURPHARMA: Transmission of shares of Mrs. Anita Chowdhury
The company has informed that a total of 66,052,814 shares of Mrs. Anita Chowdhury, mother of the following Directors of the company, has been transmitted to her legal heirs as per the Succession Certificate issued by the Honorable Court. The shares have been transmitted as follows: (cont.)
06 Nov, 2024
SQURPHARMA: Board Meeting schedule under LR 16(1)
As per Regulation 16(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on November 14, 2024 at 3:00 PM to consider, among others, un-audited financial statements of the Company for the First Quarter (Q1) period ended September 30, 2024.
24 Oct, 2024
SQURPHARMA: Price Limit Open
There will be no price limit on the trading of the shares of the Company today (24.10.2024) following its corporate declaration.
24 Oct, 2024
SQURPHARMA: Dividend Declaration
The Board of Directors has recommended 110% Cash Dividend for the year ended June 30, 2024. Date of AGM: 18.12.2024, Time: 10:00 AM, Venue: Virtual Platform. Record Date: 21.11.2024. The Company has also reported Consolidated EPS of Tk. 23.61, Consolidated NAV per share of Tk. 142.05 and Consolidated NOCFPS of Tk. 20.90 for the year ended June 30, 2024 as against Tk. 21.41, Tk. 129.95 and Tk. 9.64 respectively for the year ended June 30, 2023. (cont.)
15 Oct, 2024
SQURPHARMA: Board Meeting schedule under LR 19(1)
As per Regulation 19(1) of the Dhaka Stock Exchange (Listing) Regulations, 2015, the Company has informed that a meeting of the Board of Directors will be held on October 23, 2024 at 3:00 PM to consider, among others, audited financial statements of the Company for the year ended June 30, 2024.
Total Records: 12 Years
| Year | Type | Cash(%) | Stock(%) | EPS | NAV | Remarks |
|---|---|---|---|---|---|---|
| 2025 | Final | 120.00% | - | 27.04 | 157.88 | 23-Oct-2025 |
| 2024 | Final | 110.00% | - | 23.61 | 142.05 | 24-Oct-2024 |
| 2023 | Final | 105.00% | - | 21.41 | 129.95 | 23-Oct-2023 |
| 2022 | Final | 100.00% | - | 20.51 | 116.70 | 23-Oct-2022 |
| 2021 | Final | 60.00% | - | 17.99 | 102.54 | 24-Oct-2021 |
| 2020 | Annual | 47.00% | 5.00% | 15.82 | 91.57 | 25-Oct-2020 |
| 2019 | Annual | 42.00% | 7.00% | 16.03 | 86.03 | 23-Oct-2019 |
| 2018 | Annual | 36.00% | 7.00% | 15.72 | 78.41 | - |
| 2017 | Annual | 35.00% | 7.50% | 15.51 | 71.47 | 17-Oct-2017 |
| 2016 | Annual | 40.00% | 10.00% | 14.80 | 57.08 | 17-Oct-2016 |
| 2015 | Annual | 30.00% | 12.50% | 10.80 | 0.00 | 21-Jul-2015 |
| 2014 | Annual | 30.00% | 15.00% | 8.36 | 0.00 | - |
30-Day Block Transactions
| Date | Max Price | Min Price | Trades | Quantity | Value (Mn) |
|---|---|---|---|---|---|
| 2026-10-06 | 217.00 | 217.00 | 4 | 425,000 | 92.225 |
| 2026-10-05 | 217.30 | 217.20 | 2 | 76,600 | 16.641 |
| 2026-10-04 | 217.30 | 217.30 | 1 | 50,000 | 10.865 |
| 2026-10-01 | 218.30 | 218.20 | 2 | 589,701 | 128.702 |
| 2026-09-30 | 218.00 | 218.00 | 1 | 127,001 | 27.686 |
| 2026-09-29 | 217.60 | 217.60 | 1 | 50,000 | 10.880 |
| 2026-09-28 | 217.80 | 217.00 | 9 | 333,500 | 72.450 |
| 2026-09-22 | 219.80 | 215.50 | 7 | 688,000 | 148.615 |
| 2026-09-21 | 216.60 | 216.60 | 2 | 50,000 | 10.830 |
| 2026-09-17 | 213.40 | 212.00 | 2 | 229,000 | 48.589 |
| 2026-09-15 | 215.00 | 211.50 | 5 | 253,000 | 53.689 |
Company Info
Trading Code
SQURPHARMA
Category : Sector
A : Pharmaceuticals & Chemicals
NAV
157.88 Tk.
P/E Audited
8.05
Paid up Capital
8,864.51 crore
Authorized Capital
10,000.00 crore
Market Capital
193,512.26 crore
Total Securities
886,451,010
Reserve & Surplus
126,893.44 crore
Website
http://www.squarepharma.com.bd
Current Shareholding
Public Holding: 24.48 Cr unit
Public: 27.62% (24.48 Cr unit)
Director: 44.15% (39.14 Cr unit)
Institute: 13.90% (12.32 Cr unit)
Foreign: 14.33% (12.70 Cr unit)
Govt: 0.00% (0.00 Cr unit)
EPS History
NAV History
Dividend History
Cash Dividend
Stock Dividend
Historical Monthly Performance
Compare cumulative monthly performance.
Best Month
-
Worst Month
-
Avg MoM
-
Positive
-
Positive Yrs
-
Historical Insight
-
Historical Seasonality
Holding Period Returns
Entry → Exit Analysis
Entry Month:
Select an entry month to view historical holding period outcomes.
* Historical performance is not indicative of future results. Historical calculations are based on past closing prices and do not constitute investment advice. Dividends are not included.
| Period Ending: |
2021
07/10/2026
|
2022
07/10/2026
|
2023
07/10/2026
|
2024
07/10/2026
|
2025
07/10/2026
|
|---|---|---|---|---|---|
| Total Revenues | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Gross Profit | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Operating Expenses | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Operating Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Pre-tax Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Net Income | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| EBITDA | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| EPS (Basic) | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash & Equivalents | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Current Assets | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Assets | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Current Liabilities | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Liabilities | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Debt | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Total Equity | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Operations | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Investing | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Cash from Financing | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Capital Expenditure | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Free Cash Flow | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
| Net Change in Cash | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 | 123,456.00 |
Unlock Full Financial Data
Upgrade to PRO to access complete historical financial statements, quarterly reports, and deep fundamental analysis.
Upgrade to PROSquare Pharmaceuticals PLC
A | Pharmaceuticals & Chemicals
Today-
15 dys-
30 dys-
3 mths-
6 mths-
1 yr-
LTP:-
Open:-
High:-
Low:-
YCP:-
Vol:-
52W H:-
52W L:-
Crct Lw:-
Circuit Up:-
Value:-
M. Cap:-
P/E (Un/A):-
EPS:-
NAV:-
Paid-up:-
Ttl Share:-
Yr end:-
Reserve:-
ROE:-
EPS Q2-
EPS Q3-
EPS ANN-
EPS Q1-
DIV-
DIV YIELD-
Last AGM: -
Record Date: -
Shareholding
(as on -)
Public
0%
Director
0%
Institute
0%
Foreign
0%
Govt.
0%
Market Overview
Loading Data...
(%)
Day Open
Total Trade
Day High
Total Volume
Day Low
Value (Cr)
MARKET STATUS
Up
Down
Unchanged
All Instruments
| Symbol | LTP | Chg% |
|---|---|---|
| Loading... | ||
Sectors
| Sector | Chg% |
|---|---|
| Loading... | |
Stock Screener
Quick Screens
| Symbol | LTP | PE |
|---|---|---|
| Run filter to see results | ||
Alerts
Favorites
Watchlists
Portfolio
My Screeners
| Symbol | LTP | PE |
|---|
Run filter to see results
Market Movers
| # | Symbol | LTP | Chg% |
|---|---|---|---|
| Loading... | |||
AI Insights
Business Pro user exclusive
Login to see